{"id":8998,"date":"2021-11-05T10:30:00","date_gmt":"2021-11-05T09:30:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/"},"modified":"2021-11-05T10:30:00","modified_gmt":"2021-11-05T09:30:00","slug":"valberedningen-utsedd-infor-irlabs-arsstamma-2022","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/","title":{"rendered":"Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022"},"content":{"rendered":"<p>[mfn_before_post]<\/p>\n<div class=\"mfn-preamble\">\n<p><strong>IRLAB (Nasdaq Stockholm: IRLAB A); Valberedningens ledam\u00f6ter inf\u00f6r \u00e5rsst\u00e4mman 2022 har nu utsetts.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Enligt instruktion f\u00f6r valberedning i IRLAB Therapeutics AB som antogs p\u00e5 \u00e5rsst\u00e4mman den 6 maj 2021 ska valberedningen, ut\u00f6ver styrelsens ordf\u00f6rande, best\u00e5 av representanter f\u00f6r de tre st\u00f6rsta aktie\u00e4garna, eller \u00e4gargrupperna, av Euroclear Sweden AB registrerade per den 31 augusti 2021.<\/p>\n<p>Efter att de tre st\u00f6rsta \u00e4garna eller \u00e4gargrupperna utsett sina representanter har valberedningen haft sitt f\u00f6rsta m\u00f6te.<\/p>\n<p>Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2022 har f\u00f6ljande sammans\u00e4ttning:<\/p>\n<ul>\n<li><strong>Daniel Johnsson<\/strong>, <em>valberedningens ordf\u00f6rande<\/em>, entrepren\u00f6r, bolagsutvecklare och investerare, utsedd av en \u00e4gargrupp som representerar cirka 21 procent av aktier och r\u00f6ster;<\/li>\n<\/ul>\n<ul>\n<li><strong>Bo Rydlinger<\/strong>, bakgrund fr\u00e5n bank- och investeringsverksamhet, utsedd av en \u00e4gargrupp som representerar cirka 15 procent av aktier och r\u00f6ster;<\/li>\n<\/ul>\n<ul>\n<li><strong>Clas Sonesson<\/strong>, forskningschef (CSO) p\u00e5 IRLAB och en av IRLAB:s grundare. Utsedd av en \u00e4gargrupp best\u00e5ende av bolagets grundare som representerar cirka 10 procent av aktier och r\u00f6ster; samt<\/li>\n<\/ul>\n<ul>\n<li><strong>Gunnar Olsson<\/strong>, styrelseordf\u00f6rande i IRLAB Therapeutics AB.<\/li>\n<\/ul>\n<p>Valberedningens ledam\u00f6ter \u00e4r utsedda av \u00e4gare som sammanlagt representerar cirka 46 procent av antalet\u00a0aktier\u00a0och\u00a0r\u00f6ster i IRLAB Therapeutics AB enligt \u00e4garf\u00f6rh\u00e5llanden per 31 augusti 2021.<\/p>\n<p>Information om valberedningens arbete samt instruktionen till valberedningen \u00e5terfinns p\u00e5 bolagets hemsida under sektionen f\u00f6r bolagsstyrning. Valberedningens f\u00f6rslag kommer att presenteras i kallelsen till \u00e5rsst\u00e4mman 2022 samt p\u00e5 bolagets hemsida: <a href=\"https:\/\/www.irlab.se\/sv\/bolagsstyrning\/bolagsstamma\/\" target=\"_blank\" rel=\"nofollow noopener\">www.irlab.se<\/a>.<\/p>\n<p>Aktie\u00e4gare som \u00f6nskar l\u00e4mna f\u00f6rslag till valberedningen ska g\u00f6ra detta skriftligen, senast den 15\u00a0januari 2022, per e-post <a href=\"mailto:info@irlab.se\" target=\"_blank\" rel=\"nofollow noopener\">info@irlab.se<\/a> eller per brev till\u00a0bolagets postadress.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information<\/strong><\/p>\n<hr\/>\n<p>Daniel Johnsson, valberedningens ordf\u00f6rande<br \/>Tel: +46 73 687 64 00<br \/>E-post:\u00a0<a target=\"_blank\" href=\"mailto:daniel.captech@gmail.com\" rel=\"nofollow noopener\">daniel.captech@gmail.com<\/a><\/p>\n<p>Gunnar Olsson, styrelsens ordf\u00f6rande<br \/>Tel: +46 70 576 14 02<br \/>E-post: <a href=\"mailto:gunnar.olsson@irlab.se\" target=\"_blank\" rel=\"nofollow noopener\">gunnar.olsson@irlab.se<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om IRLAB<\/strong><\/p>\n<hr\/>\n<p>IRLAB \u00e4r ett svenskt forsknings- och utvecklingsbolag som fokuserar p\u00e5 att utveckla nya l\u00e4kemedel f\u00f6r behandling vid Parkinsons sjukdom. Bolagets l\u00e4ngst framskridna l\u00e4kemedelskandidater, mesdopetam (IRL790) och pirepemat (IRL752), vilka b\u00e5da har genomg\u00e5tt Fas IIa-studier, \u00e4r designade f\u00f6r att behandla n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinsons sjukdom: ofrivilliga r\u00f6relser (PD-LIDs), psykos (PD-P) och symtom som \u00e4r kopplade till kognitiv f\u00f6rs\u00e4mring s\u00e5som f\u00f6rs\u00e4mrad balans och \u00f6kad risk f\u00f6r fall (PD-Fall). Genom den egenutvecklade forskningsplattformen ISP (Integrative Screening Process) uppt\u00e4cker och utvecklar IRLAB unika l\u00e4kemedelskandidater f\u00f6r sjukdomar relaterade till det centrala nervsystemet (CNS) d\u00e4r stora v\u00e4xande medicinska behov f\u00f6religger. F\u00f6rutom de kliniska kandidaterna har ISP-plattformen dessutom genererat flera CNS-program som nu \u00e4r i preklinisk fas. Projektportf\u00f6ljen innefattar en kombination av det fullt-finansierade mesdopetamprojektet, i samarbete med globala partnern Ipsen, och innovativa in-house program fr\u00e5n preklinik till Fas IIb.\u00a0 IRLAB \u00e4r noterat p\u00e5 Nasdaq Stockholms huvudlista.\u00a0Mer information p\u00e5\u00a0<a href=\"http:\/\/www.irlab.se\/\" target=\"_blank\" rel=\"nofollow noopener\">www.irlab.se<\/a>.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a target=\"_blank\" class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/40af91c6-d2fe-4d18-8ec5-87784a95bc8b\/valberedningen-utsedd-infor-irlabs-arsstamma-2022.pdf\" rel=\"nofollow noopener\">Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022<\/a><\/p>\n<\/div>\n<p>[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IRLAB (Nasdaq Stockholm: IRLAB A); Valberedningens ledam\u00f6ter inf\u00f6r \u00e5rsst\u00e4mman 2022 har nu utsetts.<\/p>\n","protected":false},"template":"","class_list":["post-8998","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-ci-nomination_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB (Nasdaq Stockholm: IRLAB A); Valberedningens ledam\u00f6ter inf\u00f6r \u00e5rsst\u00e4mman 2022 har nu utsetts.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/\",\"name\":\"Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2021-11-05T09:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022 - IRLAB","og_description":"IRLAB (Nasdaq Stockholm: IRLAB A); Valberedningens ledam\u00f6ter inf\u00f6r \u00e5rsst\u00e4mman 2022 har nu utsetts.","og_url":"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/","url":"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/","name":"Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2021-11-05T09:30:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/valberedningen-utsedd-infor-irlabs-arsstamma-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"Valberedningen utsedd inf\u00f6r IRLABs \u00e5rsst\u00e4mma 2022"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/8998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=8998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}